![ticker isonics ticker isonics](https://www.seabreeze.com.au/img/photos/windsurfing/8911265.jpg)
The IsoPet Solutions division of RDGL is focused on demonstrating the safety and therapeutic effectiveness for different animal cancers in four different university veterinary hospitals.
#TICKER ISONICS SKIN#
The Company is engaging the FDA for permission to use RadioGel TM for the treatment of advanced basal and squamous cell skin cancers.
![ticker isonics ticker isonics](https://www.seabreeze.com.au/img/photos/windsurfing/10422445.jpg)
Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside the treatment area. Currently, the Company is engaged in theĭevelopment of RadioGel TM, an Yttrium-90 based brachytherapy device, for the treatment of tumors. The strategic market sector of RDGL is isotope applications. We are excited about 2018 and maintain a firm belief in our mission to provide patient friendly solutions utilizing the unique RadioGel™ technology and to grow shareholder value.”
![ticker isonics ticker isonics](https://www.seabreeze.com.au/Img/Photos/Windsurfing/12872473.jpg)
We appreciate the continued support of our shareholders and our note holders, who as previously reported on Form 8-K, agreed to eliminate all variable price conversion through April 15, 2018. We continue to believe that our Company’s valuation does not currently reflect the underlying value of RadioGel TM and the large market opportunity in both the animal and human market. Korenko continued, “We are very excited about the prospects for RadioGel TM to treat animals and humans. We will also consider non-cancer applications, such as treating infections imbedded in bones that currently lead to amputation, which can occur is diabetic patients.” After obtaining approval to treat skin cancer, we intend to grow by expanding the cancers that we treat over time. Mike Korenko, CEO, said “Our new name better reflects the description of our current and near-term product and markets. In addition to these rebranding efforts, management anticipates qualifying the Company’s common stock for quotation on the OTCQB in the near-term with the longer-term goal of a listing on a national exchange. Our new name, which reflects the giving of life, captures the essence of our Company mission. Both of these changes represent a rebranding of the Company to reflect its focus on RadioGel TM for the treatment of skin cancer. 02, 2018 (GLOBE NEWSWIRE) - Advanced Medical Isotope Corporation (OTCPink: RDGL) announced today that it has changed its name to Vivos Inc., and that its shares are scheduled to trade under the new symbol, RDGL, on the OTC Markets on January 2, 2018. The company was founded in 1992 and is based in Golden, Colorado.Richland, WA, Jan. and changed its name to Isonics Corporation in September 1996. Isonics Corporation was formerly known as A&R Materials, Inc. It offers security services for businesses and institutions in healthcare, education, retail, manufacturing, banking, and art industries. The Life Sciences division markets and sells isotopes to the health care industry for the imaging and treatment of cancer. The Semiconductor division specializes in high quality wafer reclaim, test wafer production, wafer thinning, and custom wafer services with a focus on the 300mm market. The Homeland Security and Defense division focuses on developing solutions to protect and secure the assets and resources of clients. The company has three divisions: Homeland Security and Defense, Semiconductor, and Life Sciences. (OTCMKTS:ISON) Isonics Corporation offers homeland security products, security services, reclamation services, wafer thinning, and custom wafer products and services for the silicon industry.